1. Home
  2. ABBV
  3. ABBV News

Latest AbbVie Inc. (ABBV) News on August 8, 2025

Epkinly breaks ground in Phase III FL trial
ABBV

Pharmaceutical Technology

3 hours ago

Epkinly breaks ground in Phase III FL trial

ABBV

Argus Research

3 hours ago

Daily – Vickers Top Buyers & Sellers for 08/08/2025

ABBV

MT Newswires

20 hours ago

AbbVie Shares Rise After Upgrade From Daiwa Securities

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda
ABBV

GlobeNewswire

a day ago

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda

Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical
ABBV

GlobeNewswire

a day ago

Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
ABBV

PR Newswire

a day ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
ABBV

PR Newswire

a day ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

ABBV

MT Newswires

a day ago

Daiwa Securities Upgrades AbbVie to Outperform From Neutral, Adjusts Price Target to $214 From $190

ABBV

Morningstar Research

2 days ago

Analyst Report: Royalty Pharma plc

Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029
ABBV

GlobeNewswire

2 days ago

Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029

Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
ABBV

GlobeNewswire

2 days ago

Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi

Get Ready, JUVÉDERM® Day is Calling!
ABBV

PR Newswire

2 days ago

Get Ready, JUVÉDERM® Day is Calling!

ABBV

Argus Research

2 days ago

The Fed Stands Pat as Tariffs Kick In

Hungary's Richter says some US exports face tariff challenges, but flagship drug exempt
ABBV

Reuters

2 days ago

Hungary's Richter says some US exports face tariff challenges, but flagship drug exempt

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ABBV

Zacks

3 days ago

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
ABBV

Zacks

3 days ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?
ABBV

Barchart

3 days ago

AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?

AbbVie Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
ABBV

Simply Wall St.

3 days ago

AbbVie Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
ABBV

PR Newswire

3 days ago

Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency

ABBV

MT Newswires

3 days ago

HSBC Adjusts Price Target on AbbVie to $210 From $205, Maintains Buy Rating

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
ABBV

PR Newswire

3 days ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

Pharma CEOs downplay impact of tariffs amid rising cost concerns
ABBV

Pharmaceutical Technology

4 days ago

Pharma CEOs downplay impact of tariffs amid rising cost concerns

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
ABBV

Zacks

4 days ago

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?

ABBV

MT Newswires

4 days ago

BNP Paribas Exane Adjusts AbbVie Price Target to $197 From $195, Maintains Neutral Rating

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
ABBV

The Wall Street Journal

5 days ago

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
ABBV

Motley Fool

5 days ago

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today

3 Unstoppable Stocks to Buy in August
ABBV

Motley Fool

6 days ago

3 Unstoppable Stocks to Buy in August

3 Dividend Champion Stocks I'm Watching in 2025
ABBV

Motley Fool

6 days ago

3 Dividend Champion Stocks I'm Watching in 2025

Why AbbVie Stock Flew Higher on Friday
ABBV

Motley Fool

7 days ago

Why AbbVie Stock Flew Higher on Friday

AbbVie (ABBV) Reports Increased Sales But Lower Net Income For Q2 2025
ABBV

Simply Wall St.

7 days ago

AbbVie (ABBV) Reports Increased Sales But Lower Net Income For Q2 2025

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
ABBV

Benzinga

7 days ago

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

Why AbbVie (ABBV) Stock Is Up Today
ABBV

StockStory

7 days ago

Why AbbVie (ABBV) Stock Is Up Today

ABBV

MT Newswires

7 days ago

Goldman Sachs Adjusts AbbVie Price Target to $217 From $197, Maintains Neutral Rating

ABBV

MT Newswires

7 days ago

Morgan Stanley Hikes AbbVie Price Target to $255 From $250, Maintains Overweight Rating

ABBV

MT Newswires

7 days ago

Wolfe Adjusts Price Target on AbbVie to $235 From $220, Maintains Outperform Rating

ABBV

MT Newswires

7 days ago

Raymond James Adjusts Price Target on AbbVie to $236 From $227, Maintains Outperform Rating

ABBV

MT Newswires

7 days ago

Guggenheim Adjusts Price Target on AbbVie to $227 From $216, Maintains Buy Rating

ABBV

MT Newswires

7 days ago

Pharma Stocks Fall Pre-Bell After Trump's Letters to Companies Over Drug Pricing

Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options
ABBV

GlobeNewswire

7 days ago

Fibromyalgia Market Analysis Report 2025-2035 | Key Players Drive Competition in Expanding Treatment Options

Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases
ABBV

GlobeNewswire

7 days ago

Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases

AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
ABBV

GuruFocus.com

7 days ago

AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...

Trump doubles down on Most Favored Nation plan to target drug prices
ABBV

Pharmaceutical Technology

8 days ago

Trump doubles down on Most Favored Nation plan to target drug prices

ABBV

MT Newswires

8 days ago

Investors Digest Fed's Preferred Inflation Gauge, Driving Premarket Gains for US Equity Futures

AbbVie raises full-year earnings guidance amid acquisition drive
ABBV

Investing.com

8 days ago

AbbVie raises full-year earnings guidance amid acquisition drive

AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.
ABBV

Barrons.com

8 days ago

AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.

ABBV

MT Newswires

8 days ago

AbbVie Q2 Adjusted Earnings, Net Revenue Increase; Raises 2025 Adjusted EPS Guidance

AbbVie in Talks to Buy Gilgamesh Pharmaceuticals for $1 Billion
ABBV

GuruFocus.com

8 days ago

AbbVie in Talks to Buy Gilgamesh Pharmaceuticals for $1 Billion

AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue
ABBV

StockStory

8 days ago

AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue

ABBV

Associated Press Finance

8 days ago

AbbVie: Q2 Earnings Snapshot

AbbVie lifts profit forecast on strong demand for newer immunology drugs
ABBV

Reuters

8 days ago

AbbVie lifts profit forecast on strong demand for newer immunology drugs

AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
ABBV

PR Newswire

9 days ago

AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL
ABBV

Clinical Trials Arena

9 days ago

Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
ABBV

Motley Fool

9 days ago

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever

AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings
ABBV

StockStory

9 days ago

AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings

AbbVie (ABBV) Files sNDA For Oral VENCLEXTA Combo Regimen In CLL Treatment
ABBV

Simply Wall St.

10 days ago

AbbVie (ABBV) Files sNDA For Oral VENCLEXTA Combo Regimen In CLL Treatment

ABBV

MT Newswires

10 days ago

AbbVie Submits Application to FDA for Approval of Drug Regimen to Treat Blood Cancer

Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
ABBV

Zacks

10 days ago

Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
ABBV

PR Newswire

10 days ago

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

HS market forecast to reach $7.8bn across 7MM by 2034
ABBV

Pharmaceutical Technology

11 days ago

HS market forecast to reach $7.8bn across 7MM by 2034

Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.
ABBV

Barrons.com

11 days ago

Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.

Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
ABBV

Zacks

11 days ago

Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
ABBV

Zacks

11 days ago

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

2 Top Dividend Stocks to Buy Right Now and Hold Forever
ABBV

Motley Fool

11 days ago

2 Top Dividend Stocks to Buy Right Now and Hold Forever

Stocks Rise Pre-Bell as US, EU Strike Trade Deal; Investors Await Key Tech Earnings, Economic Data, Fed Policy Decision
ABBV

MT Newswires

11 days ago

Stocks Rise Pre-Bell as US, EU Strike Trade Deal; Investors Await Key Tech Earnings, Economic Data, Fed Policy Decision

Option Volatility And Earnings Report For July 28 – Aug 1
ABBV

Barchart

11 days ago

Option Volatility And Earnings Report For July 28 – Aug 1

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
ABBV

Insider Monkey

11 days ago

Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT

AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan
ABBV

Insider Monkey

11 days ago

AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan

The Smartest Dividend Stocks to Buy With $350 Right Now
ABBV

Motley Fool

13 days ago

The Smartest Dividend Stocks to Buy With $350 Right Now

Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
ABBV

Insider Monkey

14 days ago

Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth

Mag 7 earnings, Fed meeting, PCE, jobs report: What to Watch
ABBV

Yahoo Finance Video

14 days ago

Mag 7 earnings, Fed meeting, PCE, jobs report: What to Watch

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ABBV

Zacks

15 days ago

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
ABBV

Zacks

15 days ago

J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?

The 3 Things That Matter for AbbVie Now
ABBV

Motley Fool

15 days ago

The 3 Things That Matter for AbbVie Now

AbbVie Insiders Sell US$50m Of Stock, Possibly Signalling Caution
ABBV

Simply Wall St.

15 days ago

AbbVie Insiders Sell US$50m Of Stock, Possibly Signalling Caution

Behcet's Disease Market Research Report 2025-2035 | Key Trends, Regulatory Framework, Epidemiology, Clinical Trial Analysis, Market Dynamics
ABBV

GlobeNewswire

15 days ago

Behcet's Disease Market Research Report 2025-2035 | Key Trends, Regulatory Framework, Epidemiology, Clinical Trial Analysis, Market Dynamics

Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL
ABBV

GlobeNewswire

15 days ago

Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
ABBV

PR Newswire

15 days ago

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
ABBV

GlobeNewswire

16 days ago

Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports

Accelerating innovation in early Alzheimer’s disease diagnosis
ABBV

Medical Device Network

16 days ago

Accelerating innovation in early Alzheimer’s disease diagnosis

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances
ABBV

GlobeNewswire

16 days ago

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

AbbVie (ABBV) Outperforms Broader Market: What You Need to Know
ABBV

Zacks

17 days ago

AbbVie (ABBV) Outperforms Broader Market: What You Need to Know

Top Research Reports for NVIDIA, Amazon.com & Meta Platforms
ABBV

Zacks

17 days ago

Top Research Reports for NVIDIA, Amazon.com & Meta Platforms

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
ABBV

Zacks

17 days ago

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?

BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
ABBV

PR Newswire

17 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project

This 12 Dividend Stock Portfolio Will Pay Your Bills – Every Week
ABBV

Insider Monkey

18 days ago

This 12 Dividend Stock Portfolio Will Pay Your Bills – Every Week

Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.
ABBV

Barrons.com

18 days ago

Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
ABBV

Zacks

18 days ago

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT
ABBV

Insider Monkey

19 days ago

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT

All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year
ABBV

Motley Fool

20 days ago

All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year

Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector
ABBV

Insider Monkey

21 days ago

Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ABBV

Zacks

21 days ago

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company
ABBV

Simply Wall St.

22 days ago

AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
ABBV

Zacks

23 days ago

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing

ABBV

MT Newswires

23 days ago

Rothschild & Co Redburn Adjusts AbbVie Price Target to $240 From $239, Maintains Buy Rating

How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
ABBV

Zacks

23 days ago

How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.
ABBV

Barrons.com

23 days ago

Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.

AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
ABBV

PR Newswire

24 days ago

AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact

AbbVie (ABBV) Strengthens Pays $700M to Strengthen Oncology Portfolio with ISB 2001
ABBV

Insider Monkey

24 days ago

AbbVie (ABBV) Strengthens Pays $700M to Strengthen Oncology Portfolio with ISB 2001

Here's How to Play AbbVie Stock as it Reaches Golden Cross
ABBV

Zacks

24 days ago

Here's How to Play AbbVie Stock as it Reaches Golden Cross

AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense
ABBV

Insider Monkey

25 days ago

AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense

Share on Social Networks: